文献速递治疗药物监测与药物基因组学肝肾功能剂量调整特殊人群用药

射血分数降低心衰患者二甲双胍药物基因组学:对二甲双胍与GDF-15血浆水平的影响

Metformin Pharmacogenetics in Heart Failure Patients with Reduced Ejection Fraction: Impact on Metformin and Growth Differentiation Factor-15 Plasma Levels.
PubMed 文献 · Clin Pharmacokinet · 2026-09-28

本研究在109例接受稳定二甲双胍治疗的HFrEF合并2型糖尿病患者中,评估OCT1、OCT2、MATE1和MATE2-K基因变异对二甲双胍谷浓度和GDF-15水平的影响。结果显示上述转运体基因变异不影响二甲双胍谷浓度或GDF-15水平,但二甲双胍谷浓度存在约50倍个体间差异且与剂量、NT-proBNP及GDF-15相关。

要点

  • OCT1、OCT2、MATE1基因变异不影响HFrEF患者二甲双胍谷浓度。
  • 二甲双胍谷浓度个体间差异大(约50倍),与剂量相关。
  • 二甲双胍谷浓度与NT-proBNP及GDF-15水平相关。

核心结论

  • 在HFrEF患者中,OCT1、OCT2和MATE1转运体基因变异不影响二甲双胍稳态谷浓度或循环GDF-15水平。
  • 二甲双胍谷浓度呈现约50倍的个体间变异,且与剂量呈依赖关系。

研究设计与样本

  • 开放标签研究,纳入109例接受稳定二甲双胍治疗(中位1700 mg,范围500-3000 mg)的HFrEF合并2型糖尿病患者。
  • 对OCT1、OCT2、MATE1和MATE2-K的七个选定变异进行基因分型。
  • 二甲双胍谷浓度测定共288份样本,每份三重复,中位间隔7天(IQR 6-10天);GDF-15每人测定一次。

主要发现

  • 剂量归一化二甲双胍谷浓度均值为508 ng/L/g(范围68-3515),组内相关系数0.79。
  • 调整eGFR和末次服药时间后,二甲双胍谷浓度与OCT1(p=0.12)、OCT2(p=0.10)和MATE1(p=0.95)基因变异无关。
  • MATE2-K因变异频率不足被排除。
  • 二甲双胍剂量与谷浓度相关(R2=0.36,p<0.001),谷浓度与NT-proBNP(R2=0.31,p<0.001)及GDF-15(R2=0.51,p<0.001)相关。
  • 调整eGFR和末次服药时间后,GDF-15水平与OCT1、OCT2和MATE1基因变异无关。

临床怎么用

  • HFrEF合并2型糖尿病患者中,OCT1、OCT2、MATE1基因分型结果不应作为调整二甲双胍剂量的依据。
  • 二甲双胍谷浓度个体间差异大,临床可关注剂量与浓度关系及心衰标志物水平。

局限性

  • MATE2-K因变异频率不足未能评估。
  • 研究为开放标签设计,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study assessed plasma metformin trough steady-state concentrations and plasma growth differentiation factor-15 (GDF-15) in patients with heart failure with reduced ejection fraction (HFrEF), and evaluated the effect of genetic variations in OCT1, OCT2, MATE1, and MATE2-K on metformin trough levels and GDF-15 levels. METHODS: The study population comprised 109 HFrEF patients with type 2 diabetes on stable metformin treatment (median 1700 mg, range 500-3000) in an open-label design. Patients were genotyped for seven selected variants in OCT1, OCT2, MATE1 and MATE2-K. Plasma metformin trough measurements (288 samples) were obtained in triplicates with a median 7-day interval (interquartile range, 6-10 days). Plasma GDF-15 concentrations were measured once per patient. RESULTS: Mean dose-normalised metformin trough concentrations were 508 ng/L/g (range 68-3515) with substantial interpatient variation (intraclass correlation coefficient 0.79). Metformin trough levels were independent of genetic variants in OCT1 (p = 0.12), OCT2 (p = 0.10) and MATE1 (p = 0.95), after adjustment for estimated glomerular filtration rate (eGFR) and time since last tablet intake. MATE2-K was excluded due to insufficient variant frequency. Metformin dose correlated with trough concentrations (R2 = 0.36, p < 0.001), and metformin trough concentrations correlated with NT-proBNP levels (R2 = 0.31, p < 0.001) and with GDF-15 levels (R2 = 0.51, p < 0.001). GDF-15 levels were independent of genetic variants in OCT1, OCT2, and MATE1, after adjustment for eGFR and time since last tablet intake. CONCLUSIONS: In HFrEF patients, transporter genetic variants in OCT1, OCT2, and MATE1 did not influence metformin trough steady-state concentrations or circulating GDF-15 levels. Metformin trough levels display large (50-fold) interpatient variability and a dose-dependent relationship. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov . Unique identifier: NCT02797340.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Larsen AH, Stage TB, Christensen MMH, et al. Metformin Pharmacogenetics in Heart Failure Patients with Reduced Ejection Fraction: Impact on Metformin and Growth Differentiation Factor-15 Plasma Levels. Clin Pharmacokinet. 2026. PMID: 42804152. doi:10.1007/s40262-026-01699-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。